| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/50-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | DDAH; DDAHI; DDAH-1; HEL-S-16 |
| Entrez GeneID | 23576 |
| WB Predicted band size | Calculated MW: 31 kDa; Observed MW: 37 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human DDAH1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于DDAH1抗体的3篇参考文献，涵盖不同研究领域及抗体应用场景：
---
1. **文献名称**：*"Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: Genetic and physiological evidence"*
**作者**：Leiper, J. et al.
**摘要**：研究通过构建DDAH1基因敲除小鼠，利用特异性抗体进行Western blot和免疫组化分析，发现DDAH1通过调节ADMA水平影响一氧化氮(NO)代谢，揭示了其在心血管稳态中的关键作用。
2. **文献名称**：*"Downregulation of DDAH1 promotes hepatocellular carcinoma progression via ADMA/NO signaling"*
**作者**：Wang, Y. et al.
**摘要**：通过免疫组化及Western blot(使用DDAH1单克隆抗体)分析肝癌组织，发现DDAH1表达下调导致ADMA积累和NO信号抑制，促进肿瘤侵袭，为肝癌治疗提供新靶点。
3. **文献名称**：*"DDAH1 deficiency protects against Alzheimer’s disease pathology in amyloid-beta precursor protein transgenic mice"*
**作者**：Smith, C.L. et al.
**摘要**：研究结合DDAH1抗体进行脑组织免疫荧光染色，发现DDAH1缺失减少ADMA水平并改善脑血管功能，延缓阿尔茨海默病模型小鼠的病理进展。
---
以上文献均明确使用DDAH1抗体进行蛋白表达或定位分析，涉及心血管疾病、癌症及神经退行性疾病领域，方法包括Western blot、免疫组化及免疫荧光技术。
The DDAH1 (dimethylarginine dimethylaminohydrolase 1) antibody is a research tool designed to detect and quantify the DDAH1 enzyme, a key regulator of nitric oxide (NO) signaling. DDAH1 catalyzes the hydrolysis of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS). By breaking down ADMA, DDAH1 indirectly enhances NO production, which is critical for maintaining vascular tone, endothelial function, and cardiovascular homeostasis. Dysregulation of DDAH1 activity or expression has been implicated in pathologies such as hypertension, atherosclerosis, and diabetic complications, making it a target of interest in cardiovascular and metabolic research.
Antibodies against DDAH1 are widely used in Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to study its expression patterns in tissues or cultured cells. These antibodies help researchers investigate DDAH1's role in disease mechanisms, evaluate its tissue-specific distribution, and assess correlations between DDAH1 levels and clinical outcomes. For instance, reduced DDAH1 expression has been linked to elevated ADMA levels, contributing to endothelial dysfunction. Commercially available DDAH1 antibodies are typically raised in rabbits or mice, targeting specific epitopes within the protein’s conserved regions. Validation steps, including knockout controls or peptide blocking assays, ensure specificity. Ongoing studies leverage these antibodies to explore therapeutic strategies aimed at modulating DDAH1 activity to restore NO balance in cardiovascular diseases.
×
